Beta-2 microglobulin as a biomarker for peripheral artery disease
The present invention provides β2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.
1. A method for qualifying peripheral artery disease status in a subject comprising: (a) measuring β2-microglobulin in a biological sample from the subject; and (b) correlating the measurement or measurements with peripheral artery disease versus non-peripheral artery disease.
2. The method of claim 1 , comprising measuring a plurality of biomarkers in the biological sample in addition to β2-microglobulin.
3. The method of claim 2 , wherein said plurality of additional biomarkers includes at least one biomarker selected from the group consisting of the biomarkers lysozyme and cystatin C.
4. The method of claim 2 , wherein at least β2-microglobulin and lysozyme are measured.
5. The method of claim 2 , wherein at least β2-microglobulin and cystatin C are measured.
6. The method of claim 2 , wherein at least β2-microglobulin, cystatin C and lysozyme are measured.
7. The method of claim 2 , wherein three biomarkers are measured, and wherein said three biomarkers are β2-microglobulin, cystatin C and lysozyme.
8. The method of claim 1 , wherein β2-microglobulin is measured by mass spectrometry.
9. The method of claim 1 , wherein mass spectrometry is SELDI-MS.
10. The method of claim 1 , wherein β2-microglobulin is measured by a method other than mass spectrometry.
11. The method of claim 1 , wherein β2-microglobulin is measured by immunoassay.
12. The method of any of claims 2 - 7 , wherein at least one of the biomarkers selected from the group consisting of β2-microglobulin, cystatin C and lysozyme is measured by immunoassay.
13. The method of claim 1 , wherein the sample is blood or a blood derivative.
14. The method of claim 1 , wherein the correlating is performed by executing a software classification algorithm.
15. The method of claim 1 , further comprising: (c) reporting the status to the subject.
16. The method of claim 1 , further comprising: (c) recording the status on a tangible medium.
17. The method of claim 1 , further comprising: (c) managing subject treatment based on the status.
18. The method of claim 17 , further comprising: (d) measuring the at least one biomarker after subject management and correlating the measurement with disease progression.
19. A method for determining the course of peripheral artery disease comprising: (a) measuring, at a first time, β2-microglobulin in a biological sample from the subject; (b) measuring, at a second time, β2-microglobulin in a biological sample from the subject; and (c) comparing the first measurement and the second measurement; wherein the comparative measurements determine the course of the peripheral artery disease.